Chester County News and Community Website
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has completed enrollment in its pivotal Phase 3 Alzheimer’s disease trial, positioning the biotechnology company for two planned U.S. regulatory submissions beginning …
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial Read More
WAYNE, PA — Teleflex Inc. (NYSE: TFX) has begun enrolling patients in a global pivotal study of its Freesolve resorbable magnesium scaffold, advancing the company’s effort to bring a temporary …
Teleflex Launches Pivotal Trial for Resorbable Heart Scaffold Read More
EXTON, PA — Lungpacer Medical Inc. said a study involving 50 organ donors found that temporary diaphragm neurostimulation improved donor lung function and increased the number of lungs available for …
Lungpacer Study Links Neurostimulation to Higher Lung Transplant Rates Read More
WEST CHESTER, PA — Verrica Pharmaceuticals (Nasdaq: VRCA) has dosed the first U.S. patient in a second Phase 3 clinical trial evaluating YCANTH for common warts, expanding a late-stage development …
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion Read More
WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has received U.S. Food and Drug Administration authorization for rolling review of its New Drug Application for QTORIN rapamycin, a step that could …
Palvella Secures FDA Rolling Review for Rare Disease Drug Read More
PHOENIXVILLE, PA — PleoPharma has dosed the first patient in a Phase 3 clinical trial of an investigational treatment for cannabis withdrawal symptoms, advancing a drug candidate that could become …
PleoPharma Begins Phase 3 Trial for Cannabis Withdrawal Drug Read More
WEST CHESTER, PA — Molecular Targeting Technologies Inc. reported updated clinical data from 81 patients with gastroenteropancreatic neuroendocrine tumors treated with its experimental radiopharmaceutical EBTATE, results that the company says …
MTTI Reports Extended Disease Control Data in Neuroendocrine Tumor Study Read More WAYNE, PA — Teleflex Incorporated (NYSE: TFX) reported four-year follow-up results from a first-in-human clinical study of its Freesolve resorbable magnesium coronary scaffold, providing long-term safety data as the company …
Teleflex Reports Four-Year Data for Resorbable Heart Scaffold Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for its lead therapy targeting …
Palvella Advances Rare Disease Drug Toward FDA Filing Read More WAYNE, PA — Teleflex (NYSE: TFX) reported new clinical data supporting two of its urology products as the company prepares to divest its Interventional Urology business later this year, a …
Teleflex Reports New Data Ahead of Urology Unit Sale Read More